Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

NEW DRUGS

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

JHOP - June 2021 Vol 11, No 3 - FDA Oncology Update
Download PDF

On April 22, 2021, the FDA accelerated the approval of dostarlimab (Jemperli; GlaxoSmithKline), a PD-1 inhibitor, for the treatment of recurrent or advanced endometrial cancer with the mismatch repair-deficient (dMMR) biomarker, as determined by an FDA-approved test, in patients whose disease progressed during or after treatment with a platinum-containing chemotherapy. The FDA had granted dostarlimab a breakthrough therapy designation for this indication.

“This immunotherapy was specifically studied to target dMMR endometrial cancer and leverages scientific knowledge surrounding the mechanism of immunotherapy response in this unmet medical need population,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

Endometrial cancer is the most common gynecologic malignancy in the United States and its prevalence is increasing. Approximately 75% of patients with endometrial cancers are diagnosed at an early stage, but the treatment for advanced or recurrent disease is limited after standard first-line platinum-containing chemotherapy. Approximately 25% to 30% of patients with advanced endometrial cancer have the dMMR biomarker.

The FDA approved dostarlimab based on a single-arm, multicohort clinical trial. Of the 71 patients with dMMR recurrent or advanced endometrial cancer who received dostarlimab in this study, 42.3% had a complete or a partial response. The duration of response was ≥6 months in 93% of the patients with response to therapy with dostarlimab.

The most common side effects reported with dostarlimab included fatigue, nausea, diarrhea, anemia, and constipation. Like other immunotherapies, dostarlimab can cause serious immune-mediated side effects, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Patients with severe or life-threatening infusion-related reactions should stop taking dostarlimab. Pregnant women or those who are breastfeeding should not take dostarlimab.

The FDA may require additional clinical trials to verify the clinical benefit of dostarlimab; these studies are ongoing.

Related Items
Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection
Online First published on May 12, 2023 in FDA Oncology Update
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.